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Abstract
Introduction: Estrogens regulate the proliferation of normal and neoplastic breast epithelium. Although the intracellular
mechanisms of estrogens in the breast are largely understood, little is known about how they induce changes in the
structure of the mammary epithelium, which are characteristic of breast cancer. In vitro three dimensional (3D) cultures of
immortalised breast epithelial cells recapitulate features of the breast epithelium in vivo, including formation of growth
arrested acini with hollow lumen and basement membrane. This model can also reproduce features of malignant
transformation and breast cancer, such as increased cellular proliferation and filling of the lumen. However, a system where
a connection between estrogen receptor (ER) activation and disruption of acini formation can be studied to elucidate the
role of estrogens is still missing.
Methods/Principal Findings: We describe an in vitro 3D model for breast glandular structure development, using breast
epithelial MCF-12A cells cultured in a reconstituted basement membrane matrix. These cells are estrogen receptor (ER)a,
ERb and G-protein coupled estrogen receptor 1 (GPER) competent, allowing the investigation of the effects of estrogens on
mammary gland formation and disruption. Under normal conditions, MCF-12A cells formed organised acini, with deposition
of basement membrane and hollow lumen. However, treatment with 17b-estradiol, and the exogenous estrogens bisphenol
A and propylparaben resulted in deformed acini and filling of the acinar lumen. When these chemicals were combined with
ER and GPER inhibitors (ICI 182,780 and G-15, respectively), the deformed acini recovered normal features, such as a
spheroid shape, proliferative arrest and luminal clearing, suggesting a role for the ER and GPER in the estrogenic disruption
of acinar formation.
Conclusion: This new model offers the opportunity to better understand the role of the ER and GPER in the morphogenesis
of breast glandular structure as well as the events implicated in breast cancer initiation and progression.
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Introduction
In recent years, three dimensional (3D) cultures of immortalised
breast cells have gained immense support, as they provide a
unique opportunity to model the architecture of epithelium in vivo,
in an in vitro system [1,2]. Unlike monolayer cultures, immortalised
mammary epithelial cells grown in 3D recapitulate numerous
features of the breast epithelium in vivo, including the formation of
growth arrested polarised acini with hollow lumen and basal
deposition of basement membrane components [3,4]. These well-
organised acinar structures can also reproduce important features
of malignant transformation and breast cancer development in vivo,
such as loss of apico-basal polarity, increased cellular proliferation
and filling of the lumen [5] For these reasons, 3D epithelial
cultures in a reconstituted basement membrane matrix (Matrigel)
provide the appropriate structural and functional context for
studying the events involved in the maintenance of the morphol-
ogy and function of the glandular epithelium, as well as the events
that trigger disruption of these structures and potentially lead to
breast cancer.
Epidemiological and clinical data has provided evidence that
the estrogen receptor (ER) plays an important role in the
development and progression of breast cancer. Over 50% of all
breast cancers express ERa and approximately 70% of those
respond to therapy with anti-estrogens, such as tamoxifen, which
makes the ERa an important predictor of the likelihood of a good
response to hormonal therapy and overall prognosis. A role for
ERa in breast cancer initiation and progression has also been
suggested, as high levels of this receptor found in benign breast
epithelium have been correlated with increased risk of breast
cancer [6–8]. Nonetheless, a clear understanding of the involve-
ment of the ER in breast epithelium formation, breast carcino-
genesis and cancer progression is still missing, as well as the role of
other estrogen-responsive receptors, such as the membrane
associated G-protein coupled estrogen receptor 1 (GPER, formerly
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GPR30). Although its function in the breast is still unclear, the
presence and activation of GPER have been recently associated
with development of tumour resistance to tamoxifen [9].
These considerations emphasise the importance of developing
an in vitro model where the involvement of estrogen responsive
receptors on breast epithelial formation and subsequent tumouri-
genic transformation can be studied. Establishing a system where
many features of the breast epithelium can be recapitulated and a
connection between ER activation and carcinogenicity can be
investigated is essential to clarify the role of the ER (in particular
ERa) on breast carcinogenesis, as well as the mechanisms of
hormonal carcinogenesis associated with endogenous and synthet-
ic estrogens. However, such a model has been lacking so far.
To date, investigations of the effects of estrogens in the breast in
an in vitro 3D setting have concentrated on cultures of non-
tumorigenic ERa negative/ERb positive breast epithelial MCF-
10F cells, which were derived from the floating population of the
culture that also originated MCF-10A cells and share many of
their characteristics [10,11]. This MCF-10F cell line has been used
to investigate the effects of 17b-estradiol (E2) and its metabolites
on the formation of 3D structures which characterise normal
breast development. Work conducted by Russo and colleagues
[12–14] has revealed that E2-treated cells lose their ability to form
3D duct-like structures in a collagen matrix, have high invasive-
ness and form tumours when injected into immunodeficient mice,
all indicative of a cancerous phenotype. Similar observations were
also reported for environmental contaminants with estrogenic
activity (xenoestrogens), such as bisphenol A (BPA) and butylben-
zyl phthalate (BBP) [14] and shown to derive from genomic and
epigenetic changes. However, the role of ERa could not be
evaluated as it is lacking in these cells.
Here, we describe an in vitro 3D model for breast glandular
structure development, using non-transformed breast epithelial
MCF-12A breast cells [15]. Unlike the alternative 3D model with
MCF-12F cells mentioned above [11,14], MCF-12A cells are
ERa, ERb and GPR30 competent. This offers the opportunity to
study the involvement of these receptors in breast morphogenesis,
as well as the impact of ER agonists, such as estrogens and
estrogen-like chemicals, on mammary gland formation, disruption
and, potentially, carcinogenesis.
We observed that MCF-12A grown in matrigel under normal,
control conditions formed organised, growth arrested, spheroid
acini, with deposition of basement membrane components and
hollow lumen. Conversely, treatment of these cells with E2
disrupted the morphology of the acini and interfered with lumen
formation in a concentration-dependent manner. Interestingly, the
same magnitude of effects was not observed in 3D cultures of ERa
negative MCF-10A breast cells also treated with the hormone.
A similar effect to E2 was found with two xenoestrogens: BPA
and the cosmetic additive n-propylparaben. Exposure of MCF-
12A 3D cultures to 10 mM of these chemicals for 16 days resulted
in large, misshapen, highly disorganised acini, with extensive
lumen filling. The potential involvement of estrogen receptors in
the described effects was evaluated by combining the test
chemicals with inhibitory agents, such as the antiestrogen ICI
182,780 and the GPER antagonist G-15. Results from these co-
exposures revealed that both the nuclear and the transmembrane
receptors play a role in the estrogenic disturbance of acini
formation, as the antagonists reversed some of effects induced by
the estrogens, restoring some of the phenotypes of normal, control
structures.
Results
Characterisation of receptor status of MCF-10A and MCF-
12A cells and evaluation of ER target gene expression
Although the ER status of MCF-10A and MCF-12A cells has
been previously published [10,16], it is widely accepted that
receptor expression profiles can vary between different lots and
batches of cells. As the main aim of this work was to study the
effects of estrogenic chemicals in ER and GPER competent cells, it
was essential to confirm the status of both receptors in the cells
used here.
Our data (Figure 1A) indicated that both ER receptors (a and b)
were expressed at relatively high levels in MCF-12A. In contrast,
MCF-10A cells did not express measurable levels of ERa, while
only very low levels of ERb were detected. Both cell lines
expressed the transmembrane GPER. Similar, confirmatory
observations were made in terms of expression of the relevant
genes (ERa and b and GPER) using real-time PCR (data not
shown).
In order to confirm the presence of a functional ER and the
response of this receptor to estrogenic treatment, the regulation of
two well characterised ER-target genes was studied in both cell
lines, in the presence of E2. The first gene, TFF1 (coding for the
protein pS2) has an imperfect palindromic estrogen responsive
element (ERE) in its promoter region and is directly up-regulated
by the activated ER. PGR (coding for the progesterone receptor),
on the other hand, is up-regulated in the presence of estrogens due
to the presence of a half-ERE site in proximity to an Sp-1 binding
site [reviewed in 17].
As can be seen in figure 1B, 1 nM E2 led to a significant up-
regulation of both TFF1 and PGR in MCF-12A cells. The effect of
the hormone was reduced in the presence of the ER inhibitor ICI
182,780, an indication of the involvement of the ER in the effects
reported. Conversely, no significant regulation of either gene was
observed in MCF-10A cells, which further confirms the absence of
the ER in this cell line.
3D acini formation in MCF-10A cells in the presence of E2
We first investigated the effects of E2 on acini formation in
MCF-10A cells, which are commonly used for 3D culture studies,
but, as shown, lack ERa and present low ERb levels.
The biological processes that contribute to the development of
acinar structures in a basement membrane gel have been shown to
include initial cell proliferation, deposition of the basement
membrane and differentiation into two populations (outer and
inner cells). This is followed by the death of the centrally located
cells by apoptosis, which coincides with luminal formation [18].
Similar to previous observations [18], we found that immortalised
non-malignant MCF-10A breast cells cultured for 16 days formed
growth-arrested spheroid acini. These consisted of a single layer of
cells (Figure 2A – cell nuclei stained blue) attached to a basement
membrane (Figure 2A – basement membrane component laminin
V stained red) and surrounding a hollow lumen. Some residual
apoptotic cells (stained positive for activated caspase-3 - green)
were still present in the centre of the lumen.
When MCF-10A cells were incubated for the same period of
time with E2 (10 nM) no significant changes in the glandular
structures were observed, compared to solvent controls (Figure 2).
The acini were round and well organised, with a single layer of
cells surrounded by a basement membrane. The lumen was
completely formed, with very few residual apoptotic cells.
However, in contrast to untreated cells, a small proportion of
acini presented some slight filling of the lumen (Figure 2B), which
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seems to indicate a mild disruption of acini formation or
maintenance.
Effects of E2 on acini formation in MCF-12A cells – dose-
response studies
We repeated the experiment described above, but this time
using ER competent MCF-12A cells.
In contrast to the findings with MCF-10A cells, E2 was capable
of disrupting the 3D structure of MCF-12A acini in a concentra-
tion dependent fashion after treatment lasting for 16 days
(Figure 3). All tested concentrations of the hormone disrupted
the formation of a hollow lumen in the majority of acini. The
lowest tested concentration (1 pM) affected acini morphology only
weakly. At this concentration, there were generally normally
shaped acini with a clear basement membrane and some lumen
hollowing. At the concentrations of 10 pM and above the
disrupting effects of the hormone became progressively more
pronounced, with filled lumens and no apparent apoptotic cells. At
10 nM E2, the acinar structures were severely misshapen and
disorganised with completely filled lumen.
Effects of E2 and estrogen-like agents on acini formation
– time course analysis
We were interested in establishing the time course for MCF-
12A acini morphogenesis and investigating how the different
stages in this biological process were affected by hormonal
treatment. To this end, MCF-12A cells were cultured in 3D for
4, 8, 12 and 16 days in the presence and absence of E2 (1 nM)
(Figure 4). Similar experiments were also carried out in the
presence of the environmental estrogenic agents BPA and
propylparaben (10 mM each).
In solvent-treated cultures (negative controls) the cellular
organisation into spheroid structures with deposition of the
basement membrane occurred almost from the onset. A full
basement membrane was visible within 4 days of incubation. At
this stage, acini were still small and the internal organisation was
not clear, but structures were round and well formed. Within 8
days, control acini were larger in size, measuring an average of
96.465.2 mm in diameter (Figure 5), well organised and presented
a single layer of cells in contact with the basement membrane.
There was also clear evidence of lumen hollowing, as a large
percentage of luminal cells stained positive for activated caspase-3,
a marker for apoptosis. Further enlargement and luminal
formation occurred at day 12 in control acini, when these
increased in size to 102.064.8 mm on average. Finally, acini
reached their maximum size at 16 days of incubation, with a
diameter of 120.564.4 mm (Figure 5). At this time point, structures
were also completely hollow and growth arrested, as no further
enlargement was observed with longer incubation periods (data
not shown).
In E2 treated samples, the progress of acini formation was
clearly disrupted from very early on. At 4 days, E2 treated acini
appeared organised and well formed, but were larger than those
seen in the controls. After 8 days, E2 treated acini were not too
dissimilar from controls, as the size of the spheroid structures, as
well as the number of cells per acini, did not differ significantly
from those found in untreated samples (Figure 5). However, there
was an indication that luminal clearing was being affected or
delayed, as the relative number of central apoptotic cells was
Figure 1. Receptor status and activation of ERa, ERb and GPER in MCF-12A andMCF-10A cells. A. ERa, ERb and GPER expression detected
by immunoblotting. B. Regulation of ER-target genes. White bars represent treatment with 1 nM E2. Hatched white bars show the effects of E2 in
combination with ICI 182,780 (1 mM). Horizontal dashed line corresponds to the negative controls (0.5% ethanol), set to 1. Data are from 3
independent experiments and error bars are mean 6 SEM. **a) shows statistically significant differences (p,0.01) between treatments and controls.
**b) (p,0.01) and *b) (p,0.05) highlight significant differences between treatments with E2 tested individually and treatments with E2 combined
with ICI 182,780.
doi:10.1371/journal.pone.0045767.g001
Figure 2. Confocal images of 3D cultures of epithelial breast
MCF-10A cells grown in Matrigel for 16 days. Samples were either
treated with solvent (ethanol 0.5%) or with 10 nM E2. Obtained
structures were stained with antibody against laminin V (red) to stain
the basement membrane, antibody against activated caspase-3 (green)
to identify apoptotic cells and counterstained with To-PRO 3 to visualize
cell nuclei (blue). Cross-sections of solvent control structures show a
well delineated spheroid with a layer of viable cells in contact with the
basement membrane. Two apoptotic cells are seen in the centre of the
acini. A is representative of structures that were unaffected by estrogen
treatment, as formed structures resemble those obtained in controls. B
depicts acini that showed mild disruption after E2 treatment. Images
are representative of 3 independent experiments.
doi:10.1371/journal.pone.0045767.g002
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reduced. As seen in figure 6, the percentage of apoptotic cells in
relation to the total number of cells in the acinar structures
significantly decreased from 10.761.8, under control conditions,
to 2.4660.66 in the presence of E2. This effect on luminal
formation became even more evident after 12 days incubation. At
this time, apoptosis was inhibited, as there was little or no evidence
of activated caspase-3 in the central cells and the percentage of
apoptotic cells had decreased to 1.660.4 (compared to
7.660.99% in controls).Finally, at 16 days the full impact of E2
treatment was seen, with the hormone inducing the formation of
large, severely deformed acini with completely filled lumen. Here,
acini measured an average of 142.163.9 mm and contained
62.365.9 cells, as opposed to 120.564.4 and 37.863.9, respec-
tively, in controls. This, in combination with the distorted
morphology of the structures formed, suggested excessive prolif-
eration and indicated that cells had escaped the proliferative arrest
phenotype characteristic of a control situation.
BPA and propylparaben, both tested at a concentration of
10 mM, had a dramatic impact on acini morphogenesis (Figure 4
and 5). Similar to the natural hormone, this effect became
noticeable within 8 days of incubation, when the majority of the
structures completely lacked apoptotic cells within the lumen and
presented no evidence of luminal clearing. At this stage, both
treatments significantly reduced the percentage of apoptotic cells
found in acinar structures (Figure 6), resulting in 0.7960.6 and
0.4660.26% of apoptotic cells, respectively, in comparison to
10.761.8 in untreated controls.The differences between control
and treatments became even more obvious at 12 and 16 days
incubation. The resulting structures still presented deposition of
basement membrane, but were significantly larger than controls
(see Figure 5) and no longer had a regular spheroid shape. Cells
within the acini were disorganized, there was no evident single
layer of cells attached to the basement membrane and lumen were
completely filled. Similar to E2, acini were not growth arrested, as
they continued increasing in size throughout the treatment.
Impact of ER and GPER inhibitors on estrogen-mediated
acini disruption
As all three tested compounds are known ER agonists and are
able to activate GPER, we became interested in investigating
whether blocking the signal from these receptors would prevent
the disruptive effects of estrogens. 3D cultures of MCF-12A cells
were treated with the test chemicals (E2, 1 nM; BPA, 10 mM;
propylparaben 10 mM) in the presence of the ERa antagonist ICI
182,780 (1 mM), the GPER inhibitor G-15 (10 nM), or a
combination of both inhibitors (ICI 182,780 1 mM + G-15
10 nM) for 16 days. The inhibitors were also tested on their own
and it became apparent that they, themselves, had a small impact
on acini morphology and caused some degree of acini filling
(Figure 7A). Nevertheless, it was also observed that the presence of
both antagonists reverted to a considerable extent the acini
disruption caused by all three estrogens. As seen in figure 7, ICI
182,780 allowed E2-treated acini to regain a well organized, small,
spheroid shape and some luminal clearing. A similar observation
was made with G-15, the GPER inhibitor, where acini appeared
slightly smaller and partially hollowed, with apoptotic luminal
cells. As shown in figures 7B and 7C, although the presence of the
inhibitors failed to have a dramatic impact on the size of acini
(although G-15 yielded a significant effect), both inhibitors
significantly decreased the number of cells found in each acini,
which is reflected in the ratio cell number/acini size (Figure 7D).
Figure 3. Dose-response analysis of 3D cultures of MCF-12A cells grown in Matrigel for 16 days in the presence of E2. Cells were
either incubated with solvent (ethanol 0.5%) or with increasing concentrations of E2. Resulting samples were treated with antibodies against laminin
V (red), activated caspase-3 (green) and nuclei visualized with To-PRO 3 (blue), and subsequently analysed by confocal microscopy. Images are
representative of each one of the treatments and 3 independent experiments.
doi:10.1371/journal.pone.0045767.g003
Figure 4. Time-course analysis of the formation of MCF-12A
acini cultured in matrigel in the presence of the test chemicals.
Cells were either treated with solvent (ethanol 0.5%) or with 1 nM E2,
10 mM BPA or 10 mM propylparaben and allowed to grow for 4, 8, 12
and 16 days. The resulting structures were immunostained with
antiserum to laminin V (red) to delineate the secretion of basement
membrane, activated caspase-3(green) to detect apoptotic cells and
counterstained with TO-PRO 3 to visualize the cell nuclei. Confocal
images are representative of 3 independent experiments.
doi:10.1371/journal.pone.0045767.g004
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This ratio was significantly reduced for samples treated with E2 +
ICI 182,780 and E2 + ICI 182,780 + G-15, in relation to those
treated with E2 alone. This indicates that the reduction in cell
number was not proportional to the reduction in acini size,
suggesting it was related to increased hollowing and not just a
consequence of smaller acini. These inhibitors also seemed to
affect the deregulation of acinar formation caused by the
environmental estrogens. In the case of BPA, both inhibitors
caused a reduction of acini size in comparison to those resulting
from BPA treatment alone (Figure 7B). Structures were also more
organised and spheroidal, with some evidence of lumen hollowing,
which was demonstrated by a strong reduction in cell number
within acinar structures (Figure 7C) and a reduction of the ratio
cell number/acini size (Figure 7D). With propylparaben, struc-
tures formed in the presence of ICI 182,780 and G-15 were
smaller (Figure 7B), but still presented a completely filled lumen
and no signs of apoptosis. In this case, it seemed clear that the
reduction in cell number was a consequence of a reduction in acini
size, and not luminal clearing, as the ratio cell number/acinar size
remained similar to that determined for propylparaben alone
(figure 7D).
Interestingly, the combination of ICI 182,780 and G-15 had a
greater impact on the effects of E2 and BPA, yielding structures
that resembled control acini in many ways. These were structurally
Figure 5. Quantification of acini size and cell number/acini. The size of acini (mm) and the number of cells per acini were determined by
analyzing confocal images of the incubation periods of 8, 12 and 16 days. Data corresponds to mean 6 SEM and results from three independent
experiments, where a minimum of 10 representative acini were analysed per experiment. * (p,0.05), ** (p,0.01) and *** (p,0.001) indicate
significant differences between treatments and controls.
doi:10.1371/journal.pone.0045767.g005
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organised and partially hollow, suggesting the inhibition of both
ER and GPER reduced the disrupting effects of both chemicals.
This was further supported by the ratio cell number/acini size,
which decreased significantly for both chemicals in the presence of
both inhibitors (Figure 7D), indicating a lower number of cells and,
consequently, acinar hollowing. On the other hand, although the
malformations caused by propylparaben were reduced by the
inhibitors (especially in relation to size), apoptosis seemed largely
unaffected, as acini were still completely filled and the ratio cell
number/acini size remained unaltered. This highlighted the
possibility that other factors might be at play here.
Discussion
For the first time, we show that the endogenous hormone E2
and the environmental estrogens BPA and propylparaben are able
to disrupt the correct formation of acini in 3D cultures of ERa,
ERb and GPER competent MCF-12A normal breast cells. The
extent of these abnormalities differed depending on the compound
and concentration, but overall they were characterised by the
formation of aberrant, highly proliferative and disorganised acini,
with filled lumen. As demonstrated previously, [4,18–20] normal
breast epithelial cells grown in 3D basement membrane cultures
share properties with the glandular breast epithelium in vivo as they
form hollow, organised spherical structures, with basal deposition
of basement membrane and apoptotic clearance of the luminal
cells. The development of large, misshapen acini with filled lumen
and unregulated proliferation, as seen here in the presence of our
test compounds, resembles the events that occur during the early
stages of breast cancer in humans [3,21] and could, potentially, be
indicative of neoplastic transformations.
Interestingly, a similar outcome was not observed in ERa
negative MCF-10A cells treated with E2, where the hormone
induced only mild effects, hardly distinguishable from those
observed in controls. As shown here, MCF-12A differ from MCF-
10A cells in that they express the ERa, raising the possibility that
the marked acini disruption caused by E2 in MCF-12A cultures is
somewhat dependent on the presence of ERa. This hypothesis is
further supported by our observations that blocking of receptor
signalling by using a combination of ICI 182,780 or G-15 with the
test compounds reverted the disrupting effects of the estrogens to a
large degree in MCF-12A cultures. The evidence that these
inhibitors prevented, to a large extent, the damaging effects of E2,
BPA and propylparaben to the 3D glandular structures, highlights
a role for these receptors in the actions of estrogens (natural and
man-made) in the breast glandular morphogenesis and mainte-
nance.
Work conducted previously with MCF-10A cells has shown that
the correct functioning and organisation of 3D acini depends on a
fine balance between cell proliferation and cell death (apoptosis).
An overstimulation or perturbation of these processes will lead to
aberrations in glandular structure, such as formation of large
misshapen acini with filled lumen and no apico-basal polarity
[20,22–25]. To date, a number of mechanisms responsible for cell
proliferation and apoptosis have been identified as playing an
important role in the development and maintenance of acini.
These include receptor tyrosine kinases, such as type I insulin-like
growth factor receptor (IGFIR) and epidermal growth factor
receptor (EGFR), signal transduction pathways, such as PI3K/Akt
and Ras/Raf/Erk and cell cycle and apoptosis regulating genes,
like cyclin D1 and Bcl-XL [23–26]. Often, deregulation of acinar
structures arises when one or more of these pathways are
overactivated or blocked. For example, in 3D cultures of MCF-
10A cells, hyperactivation of the PI3K/Akt cascade induces
deregulation of acini polarity [27] as well as the disruption of cell
size and proliferation, resulting in the formation of large, deformed
structures. Also, when combined with an upregulation of the
oncoprotein cyclin D1, the hyperactivation of PI3K/Akt or EGF
signaling [22,25] promote uncontrolled cell proliferation and
evasion from proliferative arrest in MCF-10A spheroids. Addi-
tionally, when these strong proliferative signals occur simulta-
neously with apoptosis inhibition, either by hyperactivation of
anti-apoptotic genes, such as Bcl-2 or by the reduced expression of
pro-apoptotic genes, such as BIM, the unregulated growth of acini
is accompanied by filling of the lumen [23,26].
From the data presented here, it can be noted that the tested
chemicals had an impact on both biological processes, cell
proliferation and apoptosis, within the acinar structures and the
blocking of the estrogen receptors (ER and GPER) seemed to
preserve the original features of the spheroids, also in relation to
both processes. The formation of large, deformed structures,
sometimes presenting multiacinar phenotypes, indicated that the
treated cells escaped proliferative arrest and were actively growing
as cultures progressed. On the other hand, the reduction of cell
death was evidenced by a reduced number of apoptotic cells as
soon as day 8 and the completely filled lumen seen at the end of
the experiment. Interestingly. The presence of the inhibitors ICI
182,780 and G-15 led to the formation of acini which were smaller
in size and spheroid in shape, suggesting proliferative arrest had
been restored. Moreover, especially in in the cases of E2 and BPA,
luminal clearance was clearly visualised following co-incubation
with ICI182,780 and ICI 182,780 + G-15. However, and in spite
of the dramatic reduction in cell number in the presence of the
inhibitors, these antagonists failed to completely revert the acinar
filling induced by the estrogens.
In addition to the well documented direct activation of the
nuclear ER and subsequent regulation of ER-target genes
(genomic events), estrogens (endogenous and exogenous), such as
E2 and BPA, also rapidly and transiently activate signal
transduction pathways, such as the PI3K/Akt, Src/Ras/Erk and
PKC cascades, via a cell membrane associated ER (non-genomic
effects) [28] and GPER [29–31]. It is believed that these genomic
and non-genomic pathways converge to influence cell proliferation
Figure 6. Quantification of the percentage of apoptotic cells
per acini. The percentage of apoptotic cells was calculated for 8, 12
and 16 days incubation periods. This was determined as the number of
cells positive to activated caspase-3 (stained green) over the total
number of cells in each acini. Data corresponds to mean 6 SEM from
three independent experiments (10 acini/experiment were analysed). *
(p,0.05) and ** (p,0.01) denote significant differences between
treatment and controls at the corresponding incubation periods.
doi:10.1371/journal.pone.0045767.g006
Impact of Estrogens on Mammary Acini In Vitro
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e45767
and apoptotic processes [32]. Significantly, this cross-talk between
ER and growth factor signalling has also been linked to genomic
instability in cancer cells [33] and the development of resistance to
hormone therapy [34].
As well as the second-messenger signalling cascades mentioned
above, a number of other factors known to be involved in acini
maintenance and formation have also been reported to be targets
of estrogenic action. For example, cyclin D1, which has been
identified as an important regulator of acinar development and
proliferation arrest, is also regulated by estrogens, both via the
genomic and the non-genomic routes in breast cancer cells. We
and others have shown that the transcription of CCDN1 (the gene
coding for cyclin D1) can be up-regulated by direct activation of
the nuclear ER and in an ER-independent fashion by E2 and
estrogen-like chemicals [32,35]. This culminates in an up-
regulation of the cyclin D1 mRNA and protein, leading,
consequently, to an increase in cell division and proliferation
[36]. Similar reported targets of estrogenic activity are apoptosis
regulating factors, such as Bcl-xL and Bcl-2 [37]. Estrogens
increase the expression of anti-apoptotic Bcl-2 and Bcl-xL in
normal and breast cancer cells, directly by interacting with the ER
[38,39], and indirectly via signalling cascades, such as PI3K [40].
Environmental contaminants, such as BPA, have also been shown
to activate Bcl-2 in breast cancer cells in a similar way to E2 [41].
Based on these considerations, it is plausible that the interaction of
estrogens with the ER, GPER and signalling cascades in 3D
cultures of normal breast cells results in similar outcomes, inducing
increased cell growth and decreased cell death. The changes in this
balance between cell death and survival would ultimately result in
disruption of acini formation and the deformed spheroid structures
reported here.
One other important point to consider is the fact that we
observed that both ICI 182,780 and G-15 alone induced a small,
but noticeable disruption of the normal development of acini.
Toxicity of these chemicals can be ruled out, as the concentrations
used were tested in monolayer cultures of MCF-12A cells and no
evident cell death or toxicity was observed (data not shown).
Therefore, we suspect that these effects are possibly related to
Figure 7. Impact of ER and GPER inhibitors on acini disruption by estrogens. Cells were treated with the test compounds (E2, 1 nM; BPA,
10 mM; propylparaben, 10 mM) alone or in combination with ICI 182,780 (1 mM), G-15 (10 nM) or ICI 182,780 (1 mM) + G-15 (10 nM) for 16 days. A
Resulting acinar structures were immunostained as described before. Red shows laminin V and basement membrane deposition, green highlights
apoptotic cells by staining activated caspase-3 and blue shows cell nuclei (TO-PRO 3 counterstain). Images were visualized by confocal microscopy
and represent 3 experiments, run independently. B. Quantification of acinar size following treatment with estrogenic chemicals and inhibitors. White
bars represent treatment with individual compounds. Hatched white bars show the effect of the chemicals in the presence of ICI 182,780 and grey
bars of test compounds in combination with G-15. Grey hatched bars show the effect of the test chemicals when combined with ICI 182,780 + G-15.
C. Number of cells per acini. D. Ratio cell number/acini size calculated for the samples shown in B and C. For all graphs, data results from three
independent experiments (10 acini/experiment) and indicates mean 6 SEM. * (p,0.05) and ** (p,0.01) highlight significant differences between
treatments with estrogenic agents tested individually and treatments with estrogens combined with inhibitors.
doi:10.1371/journal.pone.0045767.g007
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interactions of the inhibitors with targets other than their cognate
receptors. For example, ICI 182,780, is a ‘pure’ antagonist of the
ER, but also has been shown to act as an agonist potential for
GPER [42]. In turn, this transmembrane receptor can interfere
with signalling events controlled by EGF, which is present in the
medium at low levels in order to support acini formation. As
mentioned above, EGF-responsive signalling pathways, such as the
Erk1/2 signalling cascade, are involved in breast structure
formation and maintenance. Therefore, it is possible that by
indirectly interfering with these cascades’ normal function,
inhibitors are causing a small degree of acinar aberrations, such
as filling of the lumen, mimicking some of the responses caused by
the hormones. Nevertheless, the effects caused by the inhibitors
alone are minimal compared to those seen with the estrogens and
do not seem to mask the reduction of acini disruption by the
hormones in the co-incubation scenarios.
In light of our findings and the documented importance of
signalling pathways in breast glandular maintenance, we hypothe-
sise that the effects seen with MCF-12A cells in 3D cultures are the
result of a disruption of the balance between cell proliferation and
apoptosis, which, in turn, is a consequence of the effects of
estrogens on the ER, GPER and extranuclear signalling cascades.
Moreover, as highlighted previously by Thompson et al. [43], it is
likely that ERa interplays with ERb and membrane associated
receptors, such as the GPER, to influence breast glandular
maintenance, as well as mediate breast tumour development and
growth [42]. This might, ultimately, disrupt acini morphogenesis
and lead to the abnormal structures characteristic of early stages of
breast cancer.
Work conducted by Russo and colleagues [12–14] revealed that
E2 is able to induce neoplastic phenotypes in 3D cultures of MCF-
10F cells. These are normal, immortalised ERa negative/ERb
positive breast cells, which are able to form 3D duct-like structures
in a collagen matrix. When treated with E2, these cells lose their
ductulogenic capacity, show increased invasiveness and form
tumours when subsequently injected in immunodeficient mice.
The treatment of the same cells with xenoestrogens, such as BPA
and BBP, induced comparable effects, suggesting these compounds
also have carcinogenic capabilities and could contribute to the
development and progression of breast cancer. These phenotypes
were shown to be associated with genetic and epigenetic changes,
namely chromosomal aberrations (chromosomal loss and ampli-
fication) and DNA methylations [14]. Overall, our study provides
further novel and valuable information on the effects of the
endogenous hormone and xenoestrogens in 3D cultures of normal
breast cells. In this context, our data supports the possibility that
their interaction with the ER and possible GPER also plays a
significant role, although other factors, such as genomic and
chromosomal aberrations, and epigenetic changes are also likely to
be associated with some of the carcinogenic characteristics of
estrogenic compounds.
To this date, no major advances have been made in developing
an in vitro assay that could link estrogenicity and ER activation with
potential carcinogenicity. For example, widely used reporter gene
assays for ER activation and breast cancer proliferation assays
[44–46] are of great importance in screening for estrogens and
defining ER affinity, but cannot be related to neoplastic events or
cancer development. Although the changes in acini development
and morphology reported here share many similarities with those
observed in the early stages of breast cancer, it is still unclear if the
abnormal acini seen in MCF12A are, in fact, representative of a
neoplastic phenotype and result from neoplastic transformations
induced by estrogenic compounds. Further work, fully validating
this 3D in vitro model and characterising the nature of MCF-12A
acini changes following treatment is now of utmost importance.
The optimisation of a 3D system in ER competent cells, where
neoplastic phenotypes can be defined and investigated, would
present a valuable framework to dissect the role of the ER in breast
morphogenesis and cancer development, both at cellular and
tissue level. This would include investigating interaction between
different types of receptors and the cross-talk between estrogens
and other signalling pathways. Moreover, such a system would
also provide a platform to test novel steroidal estrogen receptor
modulators (SERMS) and anti estrogens, as well as study
mechanisms of acquired resistance, which are still largely unknown
and pose a major problem to breast cancer anti-hormonal
treatment.
Materials and Methods
Chemicals
17b-estradiol (E2, 98%, Sigma-Aldrich, Dorset, UK), BPA
(.99%; Sigma-Aldrich), n-propylparaben (.99%, Sigma-Aldrich)
and ICI 182,780 (a kind gift from Dr. Ian White at the MRC
Molecular Endocrinology Group, Leicester, UK) were solubilised
in ultrapure HPLC-grade ethanol as 1 mM stocks. G-15 (Sigma-
Aldrich) was prepared as 1 mM stock in DMSO. Together with
subsequent dilutions, stocks were kept at 220uC, in critically clean
glass containers. EGF (Sigma-Aldrich) was prepared as a 100 mg/
ml stock in reconstitution solution (0.2 mm-filtered 10 mM acetic
acid containing 0.1% bovine serum albumin, BSA). This solution
was also stored at 220uC.
All reagents were purchased from Sigma-Aldrich unless stated
otherwise.
Routine cell culture
Non-transformed breast epithelial MCF-12A and MCF-10A
cells were purchased from the American Type Cell Collection
(ATCC; LGC Standards, Middlesex, UK) and routinely main-
tained in 75 cm2 canted-neck tissue culture flasks (Greiner,
Gloucestershire, UK) in Dulbecco’s Modified Eagle Medium:
Nutrient Mixture F-12 (DMEM/F12, Invitrogen, Paisley, UK)
supplemented with 5% horse serum (HS, Invitrogen), 20 ng/ml
EGF, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 mg/
ml insulin, 0.22 mg/ml L-glutamine and 50 mg/ml Pen/Strep
(culture medium). Cells were kept in a humidified incubator, at
37uC and 5% CO2, subcultured at approximately 70% confluence
over a maximum of 10 passages and regularly tested for
Mycoplasma contamination.
Preparation of cell lysates and immunoblotting
Cell lysis and immunoblotting were performed as described
previously [46]. Briefly, cells were cultured in petri dishes in
culture medium until 70% confluence and lysed with 200 ml 4x
SDS-buffer (1 mM Tris, 20% SDS, 40% glycerol and 20% b-
mercaptoethanol, pH 6.8). Protein levels were quantified using the
Bradford assay. Approximately 50 mg total protein per sample
were submitted to SDS-PAGE and electrophoretically transferred
from the gels onto nitrocellulose membranes (Amersham, Buck-
inghamshire, UK) at 40 V for 1 hour. Membranes were blocked at
room temperature for 1 hour in TBS-T buffer (20 mM Tris-base,
0.1 M NaCl, 0.05% (v/v) Tween-20, pH 8) with 5% skimmed
milk. Incubation with primary antibody against ERa (Sigma;
1:3000 in 5% BSA/TBS-T), ERb (Epitomics, Insight Biotechnol-
ogy Ltd, Wembley, UK, 1:1000 in 5% BSA/TBS-T) and GPER
(ABcam, Cambridge, UK, 1:3000 in 5% BSA/TBS-T) was carried
overnight at 4uC with gentle agitation.
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Blots were then washed in TBS-T three times for 5 min,
incubated with secondary antibody (mouse anti-rabbit antibody,
Cell Signaling Technology, New England Biolabs, Hitchin,
Hertfordshire, UK, 1:2000 in 5% milk/TBS-T) and washed again
following the same procedure. Detection was carried out using the
ECL system according to the manufacturer’s protocol (New
England Biolabs) and luminescence captured by ECL hyperfilm
(Amersham).
Cell treatment for RNA isolation
MCF-12A and MCF-10A cells were seeded in 25 cm2 flasks at a
density of 300,000 cells per flask and grown for 24 hours in 5 ml
culture medium. Cells were then washed with 5 ml 1% Hanks’
balanced salt solution without phenol-red (HBSS, Invitrogen) and
changed into phenol red-free DMEM/F12 supplemented with 2%
HS, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 mg/
ml insulin, 0.22 mg/ml L-glutamine and 50 mg/ml Pen/Strep and
5 ng/ml EGF, where they were kept for further 24 hours.
Medium was replaced with fresh medium containing E2 (final
concentration 1 nM) or E2 (1 nM) + ICI 182,680 (1 mM), and cells
treated for 24 hours. The final ethanol concentration did not
exceed 0.5% (v/v). Controls were obtained by treating the cells
with 5% absolute ethanol. Following the dosing period cells were
harvested by the addition of 1 ml 0.25% trypsin-EDTA and
incubation at 37uC for 5 minutes. The obtained cell suspension
was used for RNA isolation.
RNA isolation, reverse transcription and real-time PCR
Total RNA was isolated from cell suspensions using Nucleospin
RNA II (Macherey-Nagel, Abgene, Epson, UK) following the
manufacturer’s instructions and approximately 2.5 mg of RNA was
reverse transcribed into cDNA as previously described (45). Real-
time PCR was performed using iQ SYBR Green Supermix (Bio-
Rad) on the CFX96 Touch Real-Time PCR Detection System
(Bio-Rad). For every amplification reaction, melting curves were
generated to ensure a single amplification product was obtained
for each gene target. Primer pairs (Table 1) were optimised as
described before (46) and purchased as high quality, purified oligos
from Eurogentec Ltd (Hampshire, UK). b-Actin was used as
internal control (reference gene) and the relative gene expression
levels were calculated using comparative 22DDCt method (47).
Results were expressed as fold increase over controls, standardised
such that values obtained in cells treated with vehicle only
(ethanol) were set to 1. The expression ratio results were tested for
statistical significance by a non-parametric Mann Whitney test.
Three-dimensional Matrigel culture
MCF-10A and MCF-12A cells were cultured in Matrigel
following the protocol described by Debnath and colleagues [17],
with slight modifications.
Wells in an eight-chamber slide were pre-coated with a layer of
100% growth factor reduced (GFR) Matrigel (45 ml/well) and
allowed to polymerise for 15 minutes. A single cell suspension was
prepared in DMEM/F12 supplemented with 2% HS, 0.5 mg/ml
hydrocortisone, 100 ng/ml cholera toxin, 10 mg/ml insulin,
0.22 mg/ml L-glutamine and 50 mg/ml Pen/Strep, 5 ng/ml
EGF and 2% GFR matrigel (assay medium), containing E2
(1 pM, 10 pM, 100 pM, 1 nM and 10 nM), BPA (10 mM) or
propylparaben (10 mM) without exceeding the final concentration
of 0.5% ethanol (solvent). For co-incubations, cells were treated
with assay media containing a combination of the individual test
agents (E2 1 nM, BPA 10 mM or propylparaben 10 mM) with
either ICI 182,780 (1 mM), G-15 (10 nM) or a combination of
both inhibitors at the same concentrations. Solvent controls were
treated in assay media with ethanol at 0.5% or 0.5% ethanol +
0.2% DMSO for the treatments containing G-15. Cells were
incubated for periods of up to 16 days for both cell lines, and the
medium replaced every 4 days with fresh assay medium containing
the test compounds. At the end of the incubation, cells were fixed
and slides analysed as described below.
Immunofluorescence and confocal microscopy
Following the incubation period, the assay medium was
removed from the chamber slides and cells fixed with freshly
prepared 2% paraformaldehyde (in PBS, pH 7.4) for 20 mins, at
room temperature. Next, cells were permeabilised with 0.5%
Triton-X in PBS for 10 min at 4uC and washed three times with
100 mM glycine (in PBS) at room temperature. Acini were then
blocked with immunofluorescence blocking buffer (IF buffer;
130 mM NaCl, 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100,
0.05% Tween-20) containing 10% of goat serum for 1.5 hours at
room temperature. This was followed by a secondary blocking
step, where cells were incubated with IFBB containing 10% goat
serum and 20 mg/ml goat anti-mouse F(ab’)2 fragment for
30 mins. Primary antibodies were diluted 1:200 in the secondary
block solution, incubated overnight at 4uC and rinsed three times
with IF buffer. The primary antibodies used were: Mouse anti-
laminin V (ABcam; 1:200 in IF buffer) and rabbit anti-cleaved
caspase-3 (Cell Signaling Technology, 1:200 in IF buffer).
Incubation with secondary antibody was in IF buffer containing
10% goat serum for 50 mins Dilution of 1:200), followed by three
washes at room temperature. Secondary antibodies were: Alexa
Fluor 488 goat anti-rabbit and Alexa Fluor 555 goat anti-mouse
(Molecular Probes, Invitrogen). Cell nuclei were counterstained
Table 1. Sequence of primers for real-time PCR.
Gene
Genebank accession
number Primer Sequence Conc (nM) Prod. size
b-actin X00351 Forward 59-TCAGCAAGCAGGAGTATG-39 300 97
Reverse 59-GTCAAGAAAGGGTGTAACG-39 300
TFF1 NM_003225 Forward 59-CCGTGAAAGACAGAATTG-39 200 119
Reverse 59-CGATGGTATTAGGATAGAAG-39 200
PR NM_000926 Forward 59-CACAGCGTTTCTATCAACTTAC-39 200 145
Reverse 59-GCAGCAATAACTTCAGACATC-39 200
doi:10.1371/journal.pone.0045767.t001
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with 5 mM TOPRO-3 (Molecular Probes) in PBS for 15 mins,
mounted with freshly prepared Prolong Antifade Reagent
(Molecular probes) and allowed to dry overnight at room temp.
Confocal microscopy analysis was carried our using the Carl Zeiss
MicroImaging, Inc. LSM510 confocal microscopy system with
LSM version 4.20. The images presented are representative of
three independent experiments.
All experiments were conducted blindly throughout treatment
and analysis.
Acini quantification and statistical analysis
Acini formation and disruption were quantified by analyzing
confocal images of acini and measuring the size, as well as the total
number of cells in a representative number of acini for each
treatment. A minimum of 10 randomly selected acini were
analysed for each independent experiment.
For experiments with ICI 182,780 and G-15, the ratio cell
number/acini size was also calculated. This allowed for the
differentiation between reduction in cell number due to acini
hollowing (increased apoptosis) or due to a decrease in acini size
(proliferative arrest). If the presence of an inhibitor leads to
reduction in cell number due to lumen hollowing, then the ratio
cell number/acini size should decrease, whereas if the number of
cells decreases solely due to smaller acini, than this ratio should not
suffer a major change.
Finally, the percentage of apoptotic cells was calculated as the
number of cells positive to activated caspase-3 (stained green) over
the total number of cells in each acini. Like before, at least 10
randomly selected acini were analysed for each independent
experiment.
Data analysis was performed using the Prism Software
(GraphPad Software, version 5.04, La Jolla, CA, USA). ANOVA
followed by Dunnett’s post-hoc test was applied to compare
treatments against negative controls, while ANOVA and Bonfer-
roni’s post-hoc test was used to compare paired samples
(treatments and inhibitors).
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